Bruna Lo Sasso1,2, Rosaria Vincenza Giglio1, Matteo Vidali3, Concetta Scazzone1, Giulia Bivona1, Caterina Maria Gambino1,2, Anna Maria Ciaccio4, Luisa Agnello1, Marcello Ciaccio1,2. 1. Department of Biomedicine, Neurosciences and Advanced Diagnostics, Institute of Clinical Biochemistry, Clinical Molecular Medicine and Laboratory Medicine, University of Palermo, 90127 Palermo, Italy. 2. Department of Laboratory Medicine, University Hospital "P. Giaccone", 90127 Palermo, Italy. 3. Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20121 Milan, Italy. 4. Unit of Clinical Biochemistry, University of Palermo, 90127 Palermo, Italy.
Abstract
(1) Background: The evaluation of anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the individual protection against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection; (2) Methods: We evaluated anti S-RBD IgG levels by indirect chemiluminescence immunoassay on Maglumi 800 (SNIBE, California) in 2248 vaccinated subjects without previous SARS-CoV-2 infection, 91 vaccinated individuals recovered from COVID-19, and 268 individuals recovered from COVID-19 who had not been vaccinated. Among those who were healthy and vaccinated, 352 subjects performed a re-dosing after about 72 days from the first measurement. (3) Results: Anti S-RBD IgG levels were lower in subjects with previous infection than vaccinated subjects, with or without previous infection (p < 0.001). No difference was observed between vaccinated subjects, with and without previous SARS-CoV-2 infection. Overall, anti-RBD IgG levels were higher in females than males (2110 vs. 1341 BAU/mL; p < 0.001) as well as in subjects with symptoms after vaccination than asymptomatic ones (2085 vs. 1332 BAU/mL; p = 0.001) and lower in older than younger subjects. Finally, a significant decrease in anti-RBD IgG levels was observed within a short period from a complete two-dose cycle vaccination. (4) Conclusions: Our results show an efficacy antibody response after vaccination with age-, time- and sex-related differences.
(1) Background: The evaluation of anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the individual protection against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection; (2) Methods: We evaluated anti S-RBD IgG levels by indirect chemiluminescence immunoassay on Maglumi 800 (SNIBE, California) in 2248 vaccinated subjects without previous SARS-CoV-2 infection, 91 vaccinated individuals recovered fromCOVID-19, and 268 individuals recovered fromCOVID-19 who had not been vaccinated. Among those who were healthy and vaccinated, 352 subjects performed a re-dosing after about 72 days from the first measurement. (3) Results: Anti S-RBD IgG levels were lower in subjects with previous infection than vaccinated subjects, with or without previous infection (p < 0.001). No difference was observed between vaccinated subjects, with and without previous SARS-CoV-2 infection. Overall, anti-RBD IgG levels were higher in females than males (2110 vs. 1341 BAU/mL; p < 0.001) as well as in subjects with symptoms after vaccination than asymptomatic ones (2085 vs. 1332 BAU/mL; p = 0.001) and lower in older than younger subjects. Finally, a significant decrease in anti-RBD IgG levels was observed within a short period from a complete two-dose cycle vaccination. (4) Conclusions: Our results show an efficacy antibody response after vaccination with age-, time- and sex-related differences.
Authors: Gian Luca Salvagno; Brandon M Henry; Giovanni di Piazza; Laura Pighi; Simone De Nitto; Damiano Bragantini; Gian Luca Gianfilippi; Giuseppe Lippi Journal: Diagnostics (Basel) Date: 2021-05-04
Authors: Jakub Swadźba; Tomasz Anyszek; Andrzej Panek; Agnieszka Chojęta; Kinga Wyrzykowska; Emilia Martin Journal: Diagnostics (Basel) Date: 2022-06-09
Authors: Sang Won Lee; Ji-Yong Moon; Sun-Kyung Lee; Hyun Lee; SeolHwa Moon; Sung Jun Chung; Yoomi Yeo; Tai Sun Park; Dong Won Park; Tae-Hyung Kim; Jang Won Sohn; Ho Joo Yoon; Sang-Heon Kim Journal: Front Immunol Date: 2021-11-25 Impact factor: 7.561
Authors: Maria Elena Pugliese; Riccardo Battaglia; Antonio Cerasa; Maria Girolama Raso; Francesco Coschignano; Angela Pagliuso; Roberta Bruschetta; Giovanni Pugliese; Paolo Scola; Paolo Tonin Journal: J Clin Med Date: 2021-12-13 Impact factor: 4.241